Literature DB >> 15358581

Role of accessory proteins of HTLV-1 in viral replication, T cell activation, and cellular gene expression.

Michael Bindhu1, Amrithraj Nair, Michael D Lairmore.   

Abstract

Human T-cell lymphotropic virus type 1 (HTLV-1), causes adult T cell leukemia/lymphoma (ATLL), and initiates a variety of immune mediated disorders. The viral genome encodes common structural and enzymatic proteins characteristic of all retroviruses and utilizes alternative splicing and alternate codon usage to make several regulatory and accessory proteins encoded in the pX region (pX ORF I to IV). Recent studies indicate that the accessory proteins p12I, p27I, p13II, and p30II, encoded by pX ORF I and II, contribute to viral replication and the ability of the virus to maintain typical in vivo expression levels. Proviral clones that are mutated in either pX ORF I or II, while fully competent in cell culture, are severely limited in their replicative capacity in a rabbit model. These HTLV-1 accessory proteins are critical for establishment of viral infectivity, enhance T-lymphocyte activation and potentially alter gene transcription and mitochondrial function. HTLV-1 pX ORF I expression is critical to the viral infectivity in resting primary lymphocytes suggesting a role for the calcineurin-binding protein p12I in lymphocyte activation. The endoplasmic reticulum and cis-Golgi localizing p12I activates NFAT, a key T cell transcription factor, through calcium-mediated signaling pathways and may lower the threshold of lymphocyte activation via the JAK/STAT pathway. In contrast p30II localizes to the nucleus and represses viral promoter activity, but may regulate cellular gene expression through p300/CBP or related co-activators of transcription. The mitochondrial localizing p13II induces morphologic changes in the organelle and may influence energy metabolism infected cells. Future studies of the molecular details HTLV-1 "accessory" proteins interactions will provide important new directions for investigations of HTLV-1 and related viruses associated with lymphoproliferative diseases. Thus, the accessory proteins of HTLV-1, once thought to be dispensable for viral replication, have proven to be directly involved in viral spread in vivo and represent potential targets for therapeutic intervention against HTLV-1 infection and disease.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15358581      PMCID: PMC2829751          DOI: 10.2741/1417

Source DB:  PubMed          Journal:  Front Biosci        ISSN: 1093-4715


  156 in total

1.  Synergistic activation of NFAT by HIV-1 nef and the Ras/MAPK pathway.

Authors:  A Manninen; G H Renkema; K Saksela
Journal:  J Biol Chem       Date:  2000-06-02       Impact factor: 5.157

2.  NF-AT activation induced by a CAML-interacting member of the tumor necrosis factor receptor superfamily.

Authors:  G U von Bülow; R J Bram
Journal:  Science       Date:  1997-10-03       Impact factor: 47.728

Review 3.  Functional activities of the human T-cell leukemia virus type I Tax oncoprotein: cellular signaling through NF-kappa B.

Authors:  K T Jeang
Journal:  Cytokine Growth Factor Rev       Date:  2001 Jun-Sep       Impact factor: 7.638

4.  X-I and X-II open reading frames of HTLV-I are not required for virus replication or for immortalization of primary T-cells in vitro.

Authors:  D Derse; J Mikovits; F Ruscetti
Journal:  Virology       Date:  1997-10-13       Impact factor: 3.616

Review 5.  The downregulation of CD4 and MHC-I by primate lentiviruses: a paradigm for the modulation of cell surface receptors.

Authors:  V Piguet; O Schwartz; S Le Gall; D Trono
Journal:  Immunol Rev       Date:  1999-04       Impact factor: 12.988

Review 6.  Geographic and molecular epidemiology of primate T lymphotropic retroviruses: HTLV-I, HTLV-II, STLV-I, STLV-PP, and PTLV-L.

Authors:  A Gessain; G de Thé
Journal:  Adv Virus Res       Date:  1996       Impact factor: 9.937

7.  The open reading frame I (ORF I)/ORF II part of the human T-cell leukemia virus type I X region is dispensable for p40tax, p27rex, or envelope expression.

Authors:  S Roithmann; C Pique; A Le Cesne; L Delamarre; D Pham; T Tursz; M C Dokhélar
Journal:  J Virol       Date:  1994-05       Impact factor: 5.103

Review 8.  T cell antigen receptor signal transduction pathways.

Authors:  D Cantrell
Journal:  Annu Rev Immunol       Date:  1996       Impact factor: 28.527

9.  Both wild-type and strongly attenuated bovine leukemia viruses protect peripheral blood mononuclear cells from apoptosis.

Authors:  F Dequiedt; E Hanon; P Kerkhofs; P P Pastoret; D Portetelle; A Burny; R Kettmann; L Willems
Journal:  J Virol       Date:  1997-01       Impact factor: 5.103

10.  Selective ablation of human T-cell lymphotropic virus type 1 p12I reduces viral infectivity in vivo.

Authors:  N D Collins; G C Newbound; B Albrecht; J L Beard; L Ratner; M D Lairmore
Journal:  Blood       Date:  1998-06-15       Impact factor: 22.113

View more
  19 in total

1.  Mouse models of human T lymphotropic virus type-1-associated adult T-cell leukemia/lymphoma.

Authors:  B Zimmerman; S Niewiesk; M D Lairmore
Journal:  Vet Pathol       Date:  2010-05-04       Impact factor: 2.221

2.  Nuclear export and expression of human T-cell leukemia virus type 1 tax/rex mRNA are RxRE/Rex dependent.

Authors:  X T Bai; U Sinha-Datta; N L Ko; M Bellon; C Nicot
Journal:  J Virol       Date:  2012-02-08       Impact factor: 5.103

3.  Enhancement of LFA-1-mediated T cell adhesion by human T lymphotropic virus type 1 p12I1.

Authors:  Seung-Jae Kim; Amrithraj M Nair; Soledad Fernandez; Lawrence Mathes; Michael D Lairmore
Journal:  J Immunol       Date:  2006-05-01       Impact factor: 5.422

4.  The SCHOOL of nature: IV. Learning from viruses.

Authors:  Alexander B Sigalov
Journal:  Self Nonself       Date:  2010-10

5.  Histone acetyltransferase (HAT) activity of p300 modulates human T lymphotropic virus type 1 p30II-mediated repression of LTR transcriptional activity.

Authors:  Bindhu Michael; Amrithraj M Nair; Antara Datta; Hajime Hiraragi; Lee Ratner; Michael D Lairmore
Journal:  Virology       Date:  2006-08-04       Impact factor: 3.616

6.  Human T-lymphotropic virus type 1 mitochondrion-localizing protein p13II sensitizes Jurkat T cells to Ras-mediated apoptosis.

Authors:  Hajime Hiraragi; Bindhu Michael; Amrithraj Nair; Micol Silic-Benussi; Vincenzo Ciminale; Michael Lairmore
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

7.  Tax protein-induced expression of antiapoptotic Bfl-1 protein contributes to survival of human T-cell leukemia virus type 1 (HTLV-1)-infected T-cells.

Authors:  Héloïse Macaire; Aurélien Riquet; Vincent Moncollin; Marie-Claude Biémont-Trescol; Madeleine Duc Dodon; Olivier Hermine; Anne-Laure Debaud; Renaud Mahieux; Jean-Michel Mesnard; Marlène Pierre; Louis Gazzolo; Nathalie Bonnefoy; Hélène Valentin
Journal:  J Biol Chem       Date:  2012-05-02       Impact factor: 5.157

8.  Human T-lymphotropic virus type 1 mitochondrion-localizing protein p13(II) is required for viral infectivity in vivo.

Authors:  Hajime Hiraragi; Seung-Jae Kim; Andrew J Phipps; Micol Silic-Benussi; Vincenzo Ciminale; Lee Ratner; Patrick L Green; Michael D Lairmore
Journal:  J Virol       Date:  2006-04       Impact factor: 5.103

9.  Genetic characterization of the complete genome of a highly divergent simian T-lymphotropic virus (STLV) type 3 from a wild Cercopithecus mona monkey.

Authors:  David M Sintasath; Nathan D Wolfe; Hao Qiang Zheng; Matthew LeBreton; Martine Peeters; Ubald Tamoufe; Cyrille F Djoko; Joseph L D Diffo; Eitel Mpoudi-Ngole; Walid Heneine; William M Switzer
Journal:  Retrovirology       Date:  2009-10-27       Impact factor: 4.602

10.  Ancient, independent evolution and distinct molecular features of the novel human T-lymphotropic virus type 4.

Authors:  William M Switzer; Marco Salemi; Shoukat H Qari; Hongwei Jia; Rebecca R Gray; Aris Katzourakis; Susan J Marriott; Kendle N Pryor; Nathan D Wolfe; Donald S Burke; Thomas M Folks; Walid Heneine
Journal:  Retrovirology       Date:  2009-02-02       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.